Effects of oral semaglutide on hospitalisation rates in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: SOUL trial results

John B. Buse¹; Nikolaus Marx²; Sharon L. Mulvagh³; John Deanfield⁴; Silvio E. Inzucchi⁵; Rodica Pop-Busui⁶; Johannes F. E. Mann⁷; Scott Emerson⁸; Neil R. Poulter⁹; Mads D.M. Engelmann¹⁰; G. Kees Hovingh¹⁰; Rohana Abdul Ghani¹¹; Aslam Amod¹²; Stephen C. Bain¹³; Pardeep S. Jhund¹⁴; Aytekin Oguz¹⁵; Michael Shechter¹⁶; Alex Videmark¹⁰; Derrick Musinga¹⁷; Amin Ouahid Hessissen¹⁰; Marie Reeberg Sass¹⁰; Darren K. McGuire¹⁸; on behalf of the SOUL Study Group